Pharma BD Deal Intelligence
Astellas acquired OSI Pharmaceuticals for $4B.
Astellas finally lands OSI after a multi-month hostile pursuit; deal seen as essential for Astellas' stated strategy of becoming a global category leader in…
Astellas Pharma finally secured OSI Pharmaceuticals with a $4 billion offer after initially launching an unsolicited bid, gaining Tarceva and a promising…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Astellas agreed to acquire OSI Pharmaceuticals for $57.50/share cash, totaling ~$4.0B. Closed June 9, 2010, providing Astellas a U.S. oncology platform anchored by Tarceva.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Astellas Pharma Inc. / OSI Pharmaceuticals (this deal) | 2010 | $4.0B | 33 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Astellas Pharma Inc. / Ganymed Pharmaceuticals | 2016 | $1.4B | 81 |
| Astellas Pharma Inc. / Sangamo Therapeutics, Inc. | 2026 | $50M | 63 |
| Astellas Pharma Inc. / Ogeda SA | 2017 | $850M | 59 |
| Astellas Pharma Inc. / Ocata Therapeutics, Inc. | 2015 | $379M | 41 |
| Astellas Pharma Inc. / Optimer Pharmaceuticals, Inc. | 2012 | $90M | 38 |
← Browse all deals · How we score deals
More: 2010 deals · Astellas Pharma Inc. deals · Oncology deals